These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28138260)

  • 1. Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.
    Dranitsaris G; Shane LG; Crowther M; Feugere G; Woodruff S
    Clinicoecon Outcomes Res; 2017; 9():65-73. PubMed ID: 28138260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
    Dranitsaris G; Shane L; Burgers L; Woodruff S
    Clin Appl Thromb Hemost; 2016 Oct; 22(7):617-26. PubMed ID: 27436663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
    Dranitsaris G; Shane LG; Galanaud JP; Stemer G; Debourdeau P; Woodruff S
    Support Care Cancer; 2017 Jul; 25(7):2093-2102. PubMed ID: 28204995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.
    Dranitsaris G; Vincent M; Crowther M
    Pharmacoeconomics; 2006; 24(6):593-607. PubMed ID: 16761906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.
    Woodruff S; Feugère G; Abreu P; Heissler J; Ruiz MT; Jen F
    J Thromb Thrombolysis; 2016 Nov; 42(4):494-504. PubMed ID: 27344439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.
    Dranitsaris G; Shane LG; Woodruff S
    J Oncol Pharm Pract; 2019 Jan; 25(1):68-75. PubMed ID: 28857713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.
    Heerey A; Suri S
    Pharmacoeconomics; 2005; 23(9):927-44. PubMed ID: 16153135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
    Woodruff S; Lee AYY; Carrier M; Feugère G; Abreu P; Heissler J
    J Thromb Thrombolysis; 2019 May; 47(4):495-504. PubMed ID: 30859370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
    Goodin S
    Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
    de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
    Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial.
    Anderson DR; Dunbar MJ; Bohm ER; Belzile E; Kahn SR; Zukor D; Fisher W; Gofton W; Gross P; Pelet S; Crowther M; MacDonald S; Kim P; Pleasance S; Davis N; Andreou P; Wells P; Kovacs M; Rodger MA; Ramsay T; Carrier M; Vendittoli PA
    Ann Intern Med; 2013 Jun; 158(11):800-6. PubMed ID: 23732713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China.
    Sun KX; Cui B; Cao SS; Huang QX; Xia RY; Wang WJ; Wang JW; Yu F; Ding Y
    Front Pharmacol; 2021; 12():716224. PubMed ID: 34744710
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
    Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
    J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LMWH in cancer patients with renal impairment - better than warfarin?
    Bauersachs RM
    Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands.
    Heisen M; Treur MJ; Heemstra HE; Giesen EBW; Postma MJ
    J Med Econ; 2017 Aug; 20(8):813-824. PubMed ID: 28521540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    Bick RL
    J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.